Distinct Humoral Response Development to Measles Virus Across Vaccine Platforms.

backgroundDifferent measles vaccine platforms protect against clinical disease, but characteristics of the resulting humoral responses remain incompletely defined.

methodsIn this study, a phage display immunoprecipitation sequencing technology, VirScan, was employed to evaluate measles viral epitope coverage by antibodies following wild-type (WT) measles virus (MeV) infection of rhesus macaques, or vaccination with a live attenuated MeV vaccine (LAMV), the triple measles-mumps-rubella vaccine (MMR), or a novel recombinant MeV hemagglutinin protein-based vaccine (rMeVH). Vaccinated animals were also challenged with WT MeV to measure antibody epitope reactivity during a recall.

resultsThe results demonstrate that WT MeV infection elicited a broader epitope reactivity profile than LAMV-containing vaccines. Also, rMeVH vaccination not only resulted in a narrow H protein-specific antibody profile, but epitopes recognized were distinct from LAMV-vaccinated or WT-challenged animals. All vaccine groups expanded the breadth of MeV-specific antibody repertoires following WT MeV challenge. In addition, MeV-specific VarScore, a measure of overall antigen binding, was positively correlated with IgG titer assessed by enzyme-linked immunosorbent assay, as well as antibody avidity and neutralizing titers.

conclusionsThe results demonstrate the distinct effects of vaccination platforms on the breadth and fine specificity of anti-measles-induced humoral responses, and the utility of VirScan for comprehensively assessing antibody epitope targets.